✉news WorldUS Politics first seen 7 h ago, last 6 h ago, peak #20

Two-Year Data for Alopecia Drug LEQSELVI Shows Sustained Efficacy

Original: New LEQSELVI® (deuruxolitinib) Two-Year Data in Severe Alopecia Areata Showed Sustained Efficacy and Safety at EADV Congress 2026

Sun Pharmaceutical announced two-year clinical data for LEQSELVI (deuruxolitinib) in severe alopecia areata, presented at the EADV Congress 2026. The results showed sustained efficacy and a consistent safety profile in patients over the extended treatment period. The findings reinforce the drug's long-term value for people with severe hair loss, though discussion so far appears limited to the announcement itself.

Why now: unclear

Sun PharmaceuticalLEQSELVIdeuruxolitinibEADV Congress 2026alopecia areata

Open on news →

Evidence

• New LEQSELVI® (deuruxolitinib) Two-Year Data in Severe Alopecia Areata Showed Sustained Efficacy and Safety at EADV Congress 2026 · PR Newswire

API: https://socialmediatrends-api.osmike.com/v1/trends/618368